Skip to main content

Wacker expanding on multiple fronts

12th July 2022

Submitted by:

Andrew Warmington

Wacker Chemie has announced plans to invest “a double-digit million euro amount” on it the new Biotechnology Centre at its corporate research facility in Munich, which is due to be operational in 2024. CEO Christian Hartel said that building it “will allow us to concentrate and intensify our research activities in the area of biotechnology. The additional capacity we will create here will accelerate the growth of our life-sciences division.”

Plans include laboratory and pilot plant areas spread across about 2,000 m2 over three floors. Research will mainly concentrate on the manufacturing process of biopharmaceuticals, especially advanced medicines, plus fermentation-based manufacture of ingredients for foods and food supplements. It will house about 90 people.

Another German site to see a recent groundbreaking ceremony (pictured) has taken place at Halle, where Wacker is building its competence centre for mRNA actives, including coronavirus vaccines. The company will invest over €100 million to triple capacity at the site. Part of the capacity will be available to the German government when required as part of its pandemic preparedness contracts.

The expansion will more than triple capacity at Halle. Plans involve a new, four-storey building, to be connected to the existing one. As well as four mRNA production lines due to be operational in two years’ time, it will contain storage areas, QC laboratories and office space. Around 200 new employees are currently being recruited, doubling numbers.

Wacker had announced during its capital market day in March that it would “significantly increase its investments in the further growth of its biotechnology business”. It aims to invest more than €80 million/year in this area in the next few years. By 2030, Wacker Biosolutions is planned to contribute around €1 billion/year to sales.

In a different division, Wacker has officially opened a new, 165,000 m2 silicones site at Panagahr, 160 km northwest of Kolkata. This is part of its Indian joint venture Wacker Metroark Chemicals (WMC), which dates back to 1988 The investment of “a mid-double-digit million euro amount” will create 100 jobs.

Panaghar will initially manufacture silicone rubber and Silmix brand ready-to-use silicone compounds for applications in electromobility, medical technology and electrical transmission and distribution. A further expansion is planned to add silicone fluids and emulsions. The site is three times larger than the existing site at Amtala, which will continue to make silicone fluids and emulsions for the cosmetics and personal care industries, and will thus double Wacker’s Indian capacity.

WMC said that sustainability was a key factor in the construction. River water for production will be supplied via pipelines to protect the groundwater reserves and it will use solar energy and renewable raw materials to generate energy and heat, including rice husk from the region around it. 

UPL to split out specialities

Indian agrochemicals giant UPL has announced plans to transfer its speciality chemicals business, including agrochemical

Submitted by:

Andrew Warmington

AI for SAPs

Together with Algo Artis, Japan’s Nippon Shokubai has developed an algorithm-based means for the production

Submitted by:

Andrew Warmington

Nippon Shokubai's API Facility in Japan

Nucleic acid API boost

Nippon Shokubai is to expand its GMP capacity for nucleic APIs tenfold It will install

Submitted by:

Andrew Warmington

Flamma's facility in Dalian

Flamma opens in China

Italian CDMO Flamma Group has officially opened its new cGMP plant at Dalian, China, where

Submitted by:

Andrew Warmington

GL Chemtec has opened a new kilo lab

GL Chemtec completes kilo lab

CDMO GL Chemtec has announced the completion of a cGMP kilo lab at Oakville, Ontario

Submitted by:

Andrew Warmington

Sterling's facility at Deeside, UK

CDMOs in ADC investments

Five CDMOs across the world have separately announced investments in antibody-drug conjugates (ADCs). Piramal Pharma is

Submitted by:

Andrew Warmington

Halozyme has dropped its approach to buy Evotec

Halozyme abandons Evotec bid

San Diego-based biopharmaceutical company Halozyme Therapeutics has withdrawn the offer it made for Evotec after

Submitted by:

Andrew Warmington

Afyren Neoxy plant

Milestones for two greentech firms

Afyren has achieved continuous production at its Afyren Neoxy plant at Clermont-Ferrand (pictured)

Submitted by:

Andrew Warmington

Origin by Ocean derives its materials from sargassum

CABB in algae biorefinery deal

CABB has agreed a strategic partnership to establish a first-in-kind algae biorefinery at its site at Kokkola

Submitted by:

Andrew Warmington

First waste-based biosurfactants

Belgian start-up AmphiStar has launched what it claims are the first fully upcycled biobased surfactants

Submitted by:

Andrew Warmington

Aether to supply Seqens

Indian firm Aether Industries has entered into a manufacturing agreement with Chemoxy International, a UK-based

Submitted by:

Andrew Warmington

New model for biocatalysts

BASF, the Austrian Research Centre of Industrial Biotechnology (ACIB) and the University of Graz in

Submitted by:

Andrew Warmington

CBE JU funds 31 more projects

The Circular Bio-based Europe Joint Undertaking (CBE JU), a €2 billion partnership between the EU

Submitted by:

Andrew Warmington

Ribbon cutting ceremony at Lubrizol's new office

Lubrizol opens London office

Lubrizol has opened a new office in Hammersmith, London. This will be home to a

Submitted by:

Andrew Warmington

Sudarshan to buy Heubach

India’s Sudarshan Chemical Industries (SCIL) has entered into a definitive agreement to acquire the Heubach

Submitted by:

Andrew Warmington

Alliance in natural fragrances

Sensegen, a US-based specialist in biotech-enabled fragrances, notably a new class of natural musk raw

Submitted by:

Andrew Warmington

Croda breaks ground in China

Croda International has broken ground for a low-carbon, multi-purpose production facility on a greenfield site

Submitted by:

Andrew Warmington

CCT collaboration for Givaudan

Flavours and fragrances giant Givaudan has agreed a research collaboration for the development of sustainable

Submitted by:

Andrew Warmington

REACH Authorisation

Candidate List ‘reaches’ 250

The European Chemicals Agency (ECHA) has added three more substances to the Candidate List of

Submitted by:

Andrew Warmington

Staff at Brenntag's newly acquired Czech site

CO2-free distribution site first

Brenntag has officially inaugurated what it claims to be the first CO2-emission-free chemical distribution site

Submitted by:

Andrew Warmington